SAN DIEGO--(BUSINESS WIRE)--Biological Dynamics Inc., a privately held molecular diagnostics company and a pioneer in the field of Alternating Current Electrokinetics (ACE)-based diagnostics, announces the appointment of the fifth member of the Board of Directors, John L. “Kip” Miller.
Mr. Miller is an accomplished executive with a proven track record of developing and growing global life science businesses, most notably at Life Technologies (now ThermoFisher Scientific) and BD Biosciences. Until 2011, he served as President of the Genetic Systems at Life Technologies, an approximately $1B division of a market-leading provider of DNA sequencing systems developed for academic research, applied market segments for human identification, and clinical diagnostics. Prior to the formation of Life Technologies, Kip served as Senior Vice President of Invitrogen (2005-2008) where he led the $500M Biodiscovery division, a leading developer of life science tools and enabling technologies for biomedical research, pharmaceutical drug discovery services, and transplantation diagnostics. Earlier in his career Mr. Miller held a variety of responsibilities at BD Biosciences including General Manager and Vice President of Sales and Services of the Americas.
Mr. Miller is actively involved with early life sciences companies. He is a co-founder and active board member of Tonbo Biosciences, and an active board member at Solulink and Cellector Corporation. Mr. Miller also served on the board of Firefly Bioworks prior to its acquisition by Abcam in 2015.
“We are excited to expand the capabilities of our board with an executive who possesses such a stellar track of growing life science businesses,” said Raj Krishnan, CEO of Biological Dynamics. “With TR(ACE)™ on its early commercialization path, our product development team will greatly benefit from Kip’s commercial and operational expertise.”
“I’m very enthusiastic about being able to contribute to Biological Dynamics’ talented team,” said Mr. Miller. “Clinical relevance of nanoparticles continues to gain acceptance in the medical community, and the ease and scalability of the ACE platform makes it a very promising player in that field. I’m confident that the TR(ACE)™ treatment response assay has immense potential to deliver value to cancer patients, providers and payors alike.”
About Biological Dynamics
Biological Dynamics is a private molecular diagnostics company located in San Diego. Our proprietary technology offers a novel, fast, and cost-effective lab-on-chip ACE platform that isolates nanoparticles from high conductance physiological solutions. Blood-based nanoparticles have been shown to be clinically relevant in a number of therapeutic areas, including oncology, transplant health, and reproductive medicine.
The company’s first product, the TR(ACE)TM assay, will utilize the platform for monitoring treatment response in oncology. TR(ACE)TM has not been cleared or approved by the U.S. Food and Drug Administration or any foreign regulatory agency.
For more information, please visit www.biologicaldynamics.com and follow on Twitter @BiodynSD